Content Rheum
Interleukin-23 Inhibition
FAQs
Click a title to watch the FAQ
​
Define, compare, and contrast humoral and cell-mediated immunity.
​
​
What is the role of the IL23/IL17 axis in rheumatic disease?
​
Provide immunologic rationale For IL23 directed therapy in PsA, PsO, and IBD.
​
Why is binding CD64+ important when discussing IL23 directed therapy?
​
How does axial PsA differ from AS clinically, genetically, and radiographically?
​
How do you interpret radiographic progression using modified-vdHS or mTSS?
​
How does real-world evidence differ from randomized controlled trials?
​
How do you interpret cDAPSA/DAPSA and MDA?
​
How do IL-23 and IL-17 inhibitors differ in clinical efficacy?
​
What is the Effect of Guselkumab on Structural Damage in PsA?
​
What Is the Clinical Significance of Structural Damage in PsA?
​
How Does The Design of APEX Differ From DISCOVER-2 To Enrich For Structural Damage?
​
Why is the mvdH-S Score Used Most Often in PsA Trials?
​
What is the Normal Role of CD64 in Innate and Adaptive Immunity?
​
What Is the Correlation of CD64 and IL-23 Expression in Inflamed Joint, Skin, and Gut Tissue?
​
What Validated Screening Tools Help Identify Potential PsA/SpA or IBD To Prompt Referral to Rheumatology or Gastroenterology?
​
What Is the Efficacy of Switching MOA to Guselkumab After Inadequate Response to a Single TNFi?
​
What Role Does Power Doppler Ultrasound Play in Detecting Subclinical Inflammation/Enthesitis?
​
What is the Importance of MRI in Assessing Axial Disease Manifestations in PsA?
MEDICATION REVIEWS
Click a title to watch the review
​
Describe the mechanism of action of guselkumab.
​​​
What is non-responder imputation and how is it utilized in clinical trials?
​
How is guselkumab dosed in PsO, PsA, and IBD?
​
What is the safety profile of guselkumab in PsO and PsA?
​
What is the efficacy of guselkumab across the GRAPPA domains?
​
What is the real-world evidence of guselkumab in PsA?​
​
What Is the Evidence For Guselkumab Efficacy In Inhibiting The Progression of Structural Damage?
​
What are the laboratory monitoring recommendations for guselkumab across PSO, PsA, and IBD?
​
​
What is the safety and efficacy profile of guselkumab in juvenile psoriatic arthritis (jPsA)?
JOURNAL CLUBS
PODCASTS
Click a title to play the podcast
The IL23/IL17 cascade and implications in the pathogenesis of PsA, PsO, and IBD.
​
CD64+ binding: description, relevance, and potential clinical implications.
​
The clinical utility of guselkumab in axial PsA.
​
The relative persistency and effectiveness of guselkumab in the real-world.
​
Unpacking the Differences: IL-23 Inhibitors in Focus
​
​Protecting Joints: Inhibiting Structural Damage in PsA With Guselkumab
